Docetaxel and carboplatin as the second-line treatment of non-small cell lung cancer

V. Hola, M. Pesek (Plzen, Czech Republic)

Source: Annual Congress 2002 - Lung cancer: treatment
Session: Lung cancer: treatment
Session type: Thematic Poster Session
Number: 2934
Disease area: Thoracic oncology

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
V. Hola, M. Pesek (Plzen, Czech Republic). Docetaxel and carboplatin as the second-line treatment of non-small cell lung cancer. Eur Respir J 2002; 20: Suppl. 38, 2934

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer
Source: Eur Respir J 2003; 22: Suppl. 45, 64s
Year: 2003

Second-line weekly docetaxel in advanced non-small cell lung cancer
Source: Eur Respir J 2001; 18: Suppl. 33, 377s
Year: 2001

Docetaxel in combination with cisplatin in patients with advanced non-small cell lung cancer
Source: Eur Respir J 2004; 24: Suppl. 48, 302s
Year: 2004

Non-small cell lung cancer treatment: chemotherapy combination gemcitabine – cisplatin – paclitaxel
Source: Eur Respir J 2004; 24: Suppl. 48, 302s
Year: 2004

Second-line weekly paclitaxel in advanced nonsmall cell lung cancer (NSCLC)
Source: Annual Congress 2003 - Advanced lung cancer treatment
Year: 2003


Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer
Source: Eur Respir J 2015; 46: 219-229
Year: 2015



Phase II study of gemcitabine plus irinotecan as second-line chemotherapy in advanced non-small cell lung cancer
Source: Annual Congress 2009 - Management of thoracic malignancies
Year: 2009

Single agent gemcitabine or docetaxel in the second-line therapy for patients with non-small cell lung cancer previously treated with platin-based chemotherapy
Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life
Year: 2013

Chemotherapy with carboplatin and gemcitabine in patients with non resectable stages of non-small cell lung cancer (non-SCLC)
Source: Eur Respir J 2007; 30: Suppl. 51, 436s
Year: 2007

A phase II study of docetaxel in combination with carboplatin in the treatment of non-small cell lung cancer patients
Source: Eur Respir J 2002; 20: Suppl. 38, 186s
Year: 2002

Gemcitabine, ifosfamide and paclitaxel in patients with untreated advanced/metastatic nonsmall cell lung cancer (NSCLC) A phase II study
Source: Eur Respir J 2003; 22: Suppl. 45, 28s
Year: 2003

Erlotinib as salvage treatment after failure to gefitinib in non-small cell lung cancer
Source: Annual Congress 2009 - Treatment of lung cancer
Year: 2009


First-line carboplatin plus pemetrexed with pemetrexed maintenance in HIV-positive patients with advanced non-squamous non-small cell lung cancer: the phase II IFCT-1001 CHIVA trial
Source: Eur Respir J, 56 (2) 1902066; 10.1183/13993003.02066-2019
Year: 2020



Implementation study: role of docetaxel after a first line cisplatinum based chemotherapy for non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2004; 24: Suppl. 48, 303s
Year: 2004

Weekly chemotherapy with cisplatin and paclitaxel in inoperable advanced non-small cell lung cancer: an extended phase II study
Source: Eur Respir J 2005; 26: Suppl. 49, 12s
Year: 2005

Vinorelbin and cisplatin in the treatment of advanced stage non-small cell lung cancer: Indian experience
Source: Annual Congress 2008 - Treatment of thoracic tumours
Year: 2008

Gemcitabine and cisplatin ( GD) as first line chemotherapy in patients with non-small-cell lung cancer (NSCLC)
Source: Eur Respir J 2002; 20: Suppl. 38, 464s
Year: 2002

First line treatment with gemcitabine plus cisplatine in non-small cell lung cancer: a comparison with etoposide plus cisplatin
Source: Eur Respir J 2005; 26: Suppl. 49, 77s
Year: 2005

Lung function evaluation in gemcitabine and concurrent radiotherapy treatment in nonsmall cell lung cancer (NSCLC)
Source: Eur Respir J 2001; 18: Suppl. 33, 376s
Year: 2001

Cost-effectiveness of afatinib versus erlotinib for the treatment of squamous non-small cell lung cancer in france after a first-line platinum based therapy
Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients?
Year: 2017